Details for Patent: 9,636,332

Which drugs does patent 9,636,332 protect, and when does it expire?

Patent 9,636,332 protects XIPERE and is included in one NDA.

This patent has twenty-nine patent family members in fifteen countries.

Summary for Patent: 9,636,332

Scope and claims summary:

Title:	Methods and devices for the treatment of ocular diseases in human subjects
Abstract:	Methods and devices are provided for targeted non-surgical administration of a drug formulation to the suprachoroidal space (SCS) of the eye of a human subject for the treatment of a posterior ocular disorder or a choroidal malady. In one embodiment, the method comprises inserting a hollow microneedle into the eye at an insertion site and infusing a drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. In one embodiment, the fluid drug formulation comprises drug nanoparticles or microparticles.
Inventor(s):	Zarnitsyn; Vladimir (Atlanta, GA), Patel; Samirkumar (Atlanta, GA), White; Daniel (Suwanee, GA), Noronha; Glenn (Atlanta, GA), Burke; Brian (Cary, NC)
Assignee:	CLEARSIDE BIOMEDICAL, INC. (Alpharetta, GA)
Application Number:	15/001,610
Patent Claim Types: see list of patent claims	Use; Formulation;

Drugs Protected by US Patent 9,636,332

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes	9,636,332					TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS

International Family Members for US Patent 9,636,332

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2013342275
Australia	2017272182
Brazil	112015010566
Canada	2890471
Canada	3121763
China	104884049